Ziopharm Oncology to Report Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 5, 2020

Rhea-AI Summary

Ziopharm Oncology, Inc. (Nasdaq: ZIOP) will host a conference call and webcast on November 5, 2020, at 4:30 pm EDT to discuss the third-quarter financial results for the period ending September 30, 2020. The call can be accessed by phone or through the Company’s website, where a recording will be available for two weeks post-event. Ziopharm focuses on immuno-oncology, using its Sleeping Beauty platform for effective T-cell therapies and gene therapy, enhancing treatment options for solid and blood cancers.

BOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast on Thursday, November 5, at 4:30 pm EDT to provide a corporate update and discuss financial results for the third quarter ended September 30, 2020.

The call can be accessed by dialing 1-800-920-9723 (U.S. and Canada) or 1-212-231-2932 (international). The passcode for the conference call is 21971110. To access the live webcast or the subsequent archived recording, visit the “Investors” section of the Ziopharm website at www.ziopharm.com. The webcast will be recorded and available for replay on the Company’s website for two weeks.

About Ziopharm Oncology, Inc.
Ziopharm Oncology is an immuno-oncology company focused on developing end-to-end cost-effective solutions using its non-viral Sleeping Beauty platform for T-cell receptor (TCR) and chimeric antigen receptor (CAR) T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 (IL-12). The Sleeping Beauty platform genetically modifies T cells with DNA plasmids to express TCRs to target neoantigens inside and outside hotspots for solid tumors and CAR to target CD19 for blood cancers using the Company’s “Rapid Personalized Manufacturing” to produce and release CAR-T as soon as the day after gene transfer. The Sleeping Beauty platform is being advanced in collaboration with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Eden BioCell. The Company is also developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including in collaboration with Regeneron Pharmaceuticals.

Ziopharm Oncology Contact:
Chris Taylor
VP, Investor Relations and Corporate Communications
T: 617.502.1881
E: ctaylor@ziopharm.com

 

FAQ

When is Ziopharm Oncology's Q3 2020 earnings call?

Ziopharm Oncology's Q3 2020 earnings call is scheduled for November 5, 2020, at 4:30 pm EDT.

How can I access the Ziopharm Oncology earnings call?

The earnings call can be accessed by dialing 1-800-920-9723 (U.S. and Canada) or 1-212-231-2932 (international), with the passcode 21971110.

What platforms is Ziopharm using for its therapies?

Ziopharm utilizes the Sleeping Beauty platform for T-cell receptor and CAR T-cell therapies, along with its Controlled IL-12 platform for brain cancer treatment.

Is there a way to replay the Ziopharm earnings call?

Yes, the webcast of the earnings call will be available for replay on Ziopharm's website for two weeks after the call.

What is the focus of Ziopharm Oncology?

Ziopharm Oncology focuses on developing immuno-oncology solutions utilizing its proprietary platforms for cancer treatment.